We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

36 hedge funds and large institutions have $7.52M invested in Lumos Pharma, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

9% more funds holding

Funds holding: 33 → 36 (+3)

7% less capital invested

Capital invested by funds: $8.05M → $7.52M (-$535K)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$145K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$96.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$29.4K
4
Wells Fargo
Wells Fargo
California
+$1.71K
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$1.69K

Top Sellers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
-$482K
2
Renaissance Technologies
Renaissance Technologies
New York
-$17.4K
3
PAG
Private Advisor Group
New Jersey
-$13.6K
4
Osaic Holdings
Osaic Holdings
Arizona
-$10.4K
5
TRCT
Tower Research Capital (TRC)
New York
-$1.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$1.33M +$1.71K +502 +0.1%
Goldman Sachs
2
Goldman Sachs
New York
$1.29M +$181 +53 +0%
Blackstone Inc
3
Blackstone Inc
New York
$1.04M -$482K -141,593 -30%
Vanguard Group
4
Vanguard Group
Pennsylvania
$776K +$29.4K +8,645 +4%
Renaissance Technologies
5
Renaissance Technologies
New York
$705K -$17.4K -5,100 -2%
AI
6
Acuitas Investments
Washington
$394K +$136 +40 +0%
JFG
7
Jefferies Financial Group
New York
$384K – – –
LPC
8
Lion Point Capital
New York
$289K – – –
GWM
9
Greenwich Wealth Management
Connecticut
$243K – – –
BCM
10
Bridgeway Capital Management
Texas
$149K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$149K – – –
BlackRock
12
BlackRock
New York
$138K – – –
Two Sigma Investments
13
Two Sigma Investments
New York
$136K +$145K +42,619 New
Two Sigma Advisers
14
Two Sigma Advisers
New York
$90K +$96.4K +28,300 New
MAM
15
Marquette Asset Management
Minnesota
$81.9K – – –
PAG
16
Private Advisor Group
New Jersey
$50.9K -$13.6K -4,000 -20%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$48.7K – – –
Envestnet Asset Management
18
Envestnet Asset Management
Illinois
$38K +$1.69K +497 +4%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$37.7K – – –
WAOI
20
Wealth Advisors of Iowa
Iowa
$37.2K – – –
State Street
21
State Street
Massachusetts
$35.2K – – –
KFI
22
Key Financial Inc
Pennsylvania
$34.7K – – –
Osaic Holdings
23
Osaic Holdings
Arizona
$14.7K -$10.4K -3,042 -40%
PAG
24
Paladin Advisory Group
Iowa
$14K – – –
Bank of America
25
Bank of America
North Carolina
$5.72K – – –
1
2

LUMO Hedge Fund Activity: Q4 2023 in Review

36 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2023, worth a combined $7.52M — down 6.6% from $8.05M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new LUMO positions and 0 closed out — a net gain of 3 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Two Sigma Investments, opening a new position worth an estimated $145K. The largest seller was Blackstone Inc, cutting an estimated $482K.

  • 36 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2023, up from 33 in Q3 2023.
  • Funds reported $7.52M of Lumos Pharma, Inc. Common Stock stock for Q4 2023, down 6.6% quarter-over-quarter.
  • 3 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2023 and 0 closed out, a net change of +3 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2023 was Two Sigma Investments, an estimated $145K added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2023 was Blackstone Inc, an estimated $482K sold.

Based on aggregated 13F filings for Q4 2023.